Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 22, 2007

Operon and DNA2.0 Ink Marketing and Technology Development Partnership

  • Operon Biotechnologies, through a partnership with DNA2.0, has entered the gene synthesis market, a growing application area for oligonucleotides.

    DNA2.0 and Operon Biotechnologies will combine their technologies and product lines. The companies believe that adding Operon's oligonucleotide production platform to DNA2.0's gene-synthesis process will increase the speed of synthesis. Operon will co-market DNA2.0's gene-synthesis services.

    “Construction of synthetic genes requires oligos of only the highest quality,” remarks Jeremy Minshull, president of DNA2.0. “Operon's fully automated oligo-synthesis process meets our exacting quality requirements and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene-synthesis marketplace.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »